Published in Int J Biochem Cell Biol on October 09, 2007
The thrombospondins. Cold Spring Harb Perspect Biol (2011) 1.52
Thrombospondin-1 modulates vascular endothelial growth factor activity at the receptor level. FASEB J (2009) 1.29
Thrombospondin-1: multiple paths to inflammation. Mediators Inflamm (2011) 1.24
Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors. Mol Cancer (2010) 1.14
Proinflammatory and profibrotic mediators: principal effectors of leiomyoma development as a fibrotic disorder. Semin Reprod Med (2010) 0.98
Thrombospondin and apoptosis: molecular mechanisms and use for design of complementation treatments. Curr Drug Targets (2008) 0.97
Targeting tumor angiogenesis with TSP-1-based compounds: rational design of antiangiogenic mimetics of endogenous inhibitors. Oncotarget (2010) 0.96
Non-peptidic thrombospondin-1 mimics as fibroblast growth factor-2 inhibitors: an integrated strategy for the development of new antiangiogenic compounds. J Biol Chem (2010) 0.94
PGF2α-F-prostanoid receptor signalling via ADAMTS1 modulates epithelial cell invasion and endothelial cell function in endometrial cancer. BMC Cancer (2010) 0.83
Flexible heteroarotinoid (Flex-Het) SHetA2 inhibits angiogenesis in vitro and in vivo. Invest New Drugs (2008) 0.83
Exploiting Surface Plasmon Resonance (SPR) Technology for the Identification of Fibroblast Growth Factor-2 (FGF2) Antagonists Endowed with Antiangiogenic Activity. Sensors (Basel) (2009) 0.83
Direct and allosteric inhibition of the FGF2/HSPGs/FGFR1 ternary complex formation by an antiangiogenic, thrombospondin-1-mimic small molecule. PLoS One (2012) 0.82
The Chick Embryo Chorioallantoic Membrane as an In Vivo Assay to Study Antiangiogenesis. Pharmaceuticals (Basel) (2010) 0.80
The histone deacetylase inhibitor butyroyloxymethyl diethylphosphate (AN-7) protects normal cells against toxicity of anticancer agents while augmenting their anticancer activity. Invest New Drugs (2010) 0.79
Identification of TAX2 peptide as a new unpredicted anti-cancer agent. Oncotarget (2015) 0.79
Disparate impact of butyroyloxymethyl diethylphosphate (AN-7), a histone deacetylase inhibitor, and doxorubicin in mice bearing a mammary tumor. PLoS One (2012) 0.78
Thrombospondin-1 as a Paradigm for the Development of Antiangiogenic Agents Endowed with Multiple Mechanisms of Action. Pharmaceuticals (Basel) (2010) 0.78
Integrating computational and chemical biology tools in the discovery of antiangiogenic small molecule ligands of FGF2 derived from endogenous inhibitors. Sci Rep (2016) 0.75
Thrombospondin-1-Based Antiangiogenic Therapy. J Ocul Pharmacol Ther (2015) 0.75
Matricellular proteins: extracellular modulators of cell function. Curr Opin Cell Biol (2002) 4.23
The thrombospondins. Int J Biochem Cell Biol (2004) 3.01
Thrombospondins as matricellular modulators of cell function. J Clin Invest (2001) 2.95
Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor. J Cell Biol (1990) 2.69
Basement membrane proteoglycans: from cellar to ceiling. Nat Rev Mol Cell Biol (2005) 2.28
The gelatin sponge-chorioallantoic membrane assay. Nat Protoc (2006) 1.77
Tumor progression: the effects of thrombospondin-1 and -2. Int J Biochem Cell Biol (2004) 1.77
Structure of a thrombospondin C-terminal fragment reveals a novel calcium core in the type 3 repeats. EMBO J (2004) 1.62
Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by beta1 integrins. J Cell Biol (2005) 1.59
Interaction of human thrombospondin with types I-V collagen: direct binding and electron microscopy. J Cell Biol (1987) 1.36
Structure of the calcium-rich signature domain of human thrombospondin-2. Nat Struct Mol Biol (2005) 1.33
Thrombospondin 1 as an enzyme inhibitor. Thromb Haemost (1994) 1.31
Identification of novel beta1 integrin binding sites in the type 1 and type 2 repeats of thrombospondin-1. J Biol Chem (2004) 1.19
Expression of recombinant matrix components using baculoviruses. Methods Cell Biol (2002) 1.15
Thrombospondin 1: a multifunctional protein implicated in the regulation of tumor growth. Crit Rev Oncol Hematol (2004) 1.13
The heparin binding 25 kDa fragment of thrombospondin-1 promotes angiogenesis and modulates gelatinase and TIMP-2 production in endothelial cells. FASEB J (2000) 1.12
A polymorphism in thrombospondin-1 associated with familial premature coronary artery disease alters Ca2+ binding. J Biol Chem (2004) 1.12
The 140-kilodalton antiangiogenic fragment of thrombospondin-1 binds to basic fibroblast growth factor. Cell Growth Differ (1997) 1.07
Thrombospondin 1 as a scavenger for matrix-associated fibroblast growth factor 2. Blood (2003) 1.07
Another dimension to calcium signaling: a look at extracellular calcium. J Cell Sci (2005) 1.07
Interactions among the three structural motifs of the C-terminal region of human thrombospondin-2. Biochemistry (2003) 1.02
Trimeric assembly of the C-terminal region of thrombospondin-1 or thrombospondin-2 is necessary for cell spreading and fascin spike organisation. J Cell Sci (2002) 1.01
Functions of the conserved thrombospondin carboxy-terminal cassette in cell-extracellular matrix interactions and signaling. Int J Biochem Cell Biol (2004) 0.99
BIACORE data processing: an evaluation of the global fitting procedure. Anal Biochem (2001) 0.96
Extracellular angiogenic growth factor interactions: an angiogenesis interactome survey. Endothelium (2006) 0.93
A polymorphism in thrombospondin-1 associated with familial premature coronary heart disease causes a local change in conformation of the Ca2+-binding repeats. J Biol Chem (2003) 0.91
Residues F16-G33 and A784-N823 within platelet thrombospondin-1 play a major role in binding human neutrophils: evaluation by two novel binding assays. J Lab Clin Med (2000) 0.90
Functional changes in the conformation of thrombospondin-1 during complexation with fibronectin or heparin. Exp Cell Res (1999) 0.84
Single-chain antibody fragments derived from a human synthetic phage-display library bind thrombospondin and inhibit sickle cell adhesion. Blood (2003) 0.84
Thrombospondins are astrocyte-secreted proteins that promote CNS synaptogenesis. Cell (2005) 7.41
Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev (2005) 4.65
Gabapentin receptor alpha2delta-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis. Cell (2009) 3.46
Cutting edge: extracellular high mobility group box-1 protein is a proangiogenic cytokine. J Immunol (2006) 2.57
MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood (2009) 2.28
Shedding of the matrix metalloproteinases MMP-2, MMP-9, and MT1-MMP as membrane vesicle-associated components by endothelial cells. Am J Pathol (2002) 2.27
Polymerization of type I and III collagens is dependent on fibronectin and enhanced by integrins alpha 11beta 1 and alpha 2beta 1. J Biol Chem (2002) 2.26
Sonographic quantitative evaluation of scrotal veins in healthy subjects: normative values and implications for the diagnosis of varicocele. Eur Urol (2006) 2.17
Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res (2003) 2.14
Bioavailability of VEGF in tumor-shed vesicles depends on vesicle burst induced by acidic pH. Neoplasia (2006) 1.98
A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica (2003) 1.97
Complexity and complementarity of outer membrane protein A recognition by cellular and humoral innate immunity receptors. Immunity (2005) 1.86
Gremlin is a novel agonist of the major proangiogenic receptor VEGFR2. Blood (2010) 1.85
Fibronectin regulates latent transforming growth factor-beta (TGF beta) by controlling matrix assembly of latent TGF beta-binding protein-1. J Biol Chem (2005) 1.82
Fibronectin fibrillogenesis regulates three-dimensional neovessel formation. Genes Dev (2008) 1.81
Mammalian tumor xenografts induce neovascularization in zebrafish embryos. Cancer Res (2007) 1.79
The gelatin sponge-chorioallantoic membrane assay. Nat Protoc (2006) 1.77
Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res (2006) 1.72
Alpha(v)beta(3) integrin engagement enhances cell invasiveness in human multiple myeloma. Haematologica (2002) 1.69
Regulator of G-protein signaling 5 (RGS5) protein: a novel marker of cancer vasculature elicited and sustained by the tumor's proangiogenic microenvironment. Cell Mol Life Sci (2011) 1.62
Nerve growth factor-endothelial cell interaction leads to angiogenesis in vitro and in vivo. FASEB J (2002) 1.61
Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr Med Chem (2006) 1.59
ADAMTS1 mediates the release of antiangiogenic polypeptides from TSP1 and 2. EMBO J (2006) 1.59
The zebrafish/tumor xenograft angiogenesis assay. Nat Protoc (2007) 1.56
Fibrillin assembly requires fibronectin. Mol Biol Cell (2008) 1.53
Tyrosine phosphorylation of type Igamma phosphatidylinositol phosphate kinase by Src regulates an integrin-talin switch. J Cell Biol (2003) 1.49
Markers of increased angiogenesis and their correlation with biological parameters identifying high-risk patients in early B-cell chronic lymphocytic leukemia. Leuk Res (2007) 1.48
The role of podoplanin in tumor progression and metastasis. Anticancer Res (2008) 1.48
Angiogenesis in pre-malignant conditions. Eur J Cancer (2009) 1.45
Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res (2003) 1.45
Angiogenesis in acute and chronic lymphocytic leukemia. Leuk Res (2004) 1.41
A portrait of Aristotle as an anatomist: historical article. Clin Anat (2007) 1.40
The adaptor protein p66Shc is a positive regulator in the angiogenic response induced by hypoxic T cells. J Leukoc Biol (2009) 1.40
Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis. Am J Pathol (2003) 1.39
Mondino de' Liuzzi and his Anothomia: a milestone in the development of modern anatomy. Clin Anat (2006) 1.38
Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. Cancer Res (2006) 1.37
Bcl-2 overexpression in human melanoma cells increases angiogenesis through VEGF mRNA stabilization and HIF-1-mediated transcriptional activity. FASEB J (2002) 1.37
A new image analysis method based on topological and fractal parameters to evaluate the angiostatic activity of docetaxel by using the Matrigel assay in vitro. Microvasc Res (2004) 1.35
Differential interactions of thrombospondin-1, -2, and -4 with CD47 and effects on cGMP signaling and ischemic injury responses. J Biol Chem (2008) 1.34
Structure of the calcium-rich signature domain of human thrombospondin-2. Nat Struct Mol Biol (2005) 1.33
Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis. J Natl Cancer Inst (2006) 1.32
Nerve growth factor as an angiogenic factor. Microvasc Res (2007) 1.32
In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature. Nat Methods (2005) 1.32
Alpha4beta1 integrin mediates selective endothelial cell responses to thrombospondins 1 and 2 in vitro and modulates angiogenesis in vivo. Circ Res (2003) 1.32
Evaluation of microvascular density in tumors: pro and contra. Histol Histopathol (2008) 1.30
Analysis of the role of chemokines in angiogenesis. J Immunol Methods (2003) 1.30
Interactions of thrombospondins with alpha4beta1 integrin and CD47 differentially modulate T cell behavior. J Cell Biol (2002) 1.29
Generation of biologically active angiostatin kringle 1-3 by activated human neutrophils. J Immunol (2002) 1.28
Interaction of alpha9beta1 integrin with thrombospondin-1 promotes angiogenesis. Circ Res (2007) 1.28
E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res (2011) 1.28
Antiangiogenic and vascular-targeting activity of the microtubule-destabilizing trans-resveratrol derivative 3,5,4'-trimethoxystilbene. Mol Pharmacol (2005) 1.27
The N-terminal 70-kDa fragment of fibronectin binds to cell surface fibronectin assembly sites in the absence of intact fibronectin. Matrix Biol (2006) 1.26
Roles of integrin activation in eosinophil function and the eosinophilic inflammation of asthma. J Leukoc Biol (2007) 1.25
Cutting edge: proangiogenic properties of alternatively activated dendritic cells. J Immunol (2005) 1.25
Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis. Blood (2004) 1.25
Lymphatics at the crossroads of angiogenesis and lymphangiogenesis. J Anat (2004) 1.22
The soluble form of a disintegrin and metalloprotease 33 promotes angiogenesis: implications for airway remodeling in asthma. J Allergy Clin Immunol (2008) 1.21
Severe alterations of endothelial and glial cells in the blood-brain barrier of dystrophic mdx mice. Glia (2003) 1.21
Fibroblast growth factor receptor-1 is essential for in vitro cardiomyocyte development. Circ Res (2003) 1.21
The natural compound n-butylidenephthalide derived from the volatile oil of Radix Angelica sinensis inhibits angiogenesis in vitro and in vivo. Angiogenesis (2011) 1.20
Identification of novel beta1 integrin binding sites in the type 1 and type 2 repeats of thrombospondin-1. J Biol Chem (2004) 1.19
Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator. Clin Cancer Res (2004) 1.19
Cathepsin B mediates the pH-dependent proinvasive activity of tumor-shed microvesicles. Neoplasia (2008) 1.19
Regulation of integrin function by CD47 ligands. Differential effects on alpha vbeta 3 and alpha 4beta1 integrin-mediated adhesion. J Biol Chem (2002) 1.18
Docetaxel versus paclitaxel for antiangiogenesis. J Hematother Stem Cell Res (2002) 1.16
The adhesion molecule NCAM promotes ovarian cancer progression via FGFR signalling. EMBO Mol Med (2011) 1.16
Gene expression profiling of bone marrow endothelial cells in patients with multiple myeloma. Clin Cancer Res (2009) 1.16
Endothelial cells in the bone marrow of patients with multiple myeloma. Blood (2003) 1.15
Enhancement of thrombogenesis by plasma fibronectin cross-linked to fibrin and assembled in platelet thrombi. Blood (2006) 1.15
Expression of recombinant matrix components using baculoviruses. Methods Cell Biol (2002) 1.15
HIV-1 matrix protein p17 promotes angiogenesis via chemokine receptors CXCR1 and CXCR2. Proc Natl Acad Sci U S A (2012) 1.15
Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin. Clin Cancer Res (2008) 1.14
Shedding of membrane vesicles mediates fibroblast growth factor-2 release from cells. J Biol Chem (2003) 1.13
Recognition of the N-terminal modules of thrombospondin-1 and thrombospondin-2 by alpha6beta1 integrin. J Biol Chem (2003) 1.13
Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma. Clin Cancer Res (2011) 1.12
A polymorphism in thrombospondin-1 associated with familial premature coronary artery disease alters Ca2+ binding. J Biol Chem (2004) 1.12
Extended binding site on fibronectin for the functional upstream domain of protein F1 of Streptococcus pyogenes. J Biol Chem (2010) 1.11